Stock Chat

Join Stock Chat and Discuss this DD Report

We are excited to present Merck KGaA (OTC: MKGAF).

Full DD Report for MKGAF

Recent News from (OTC: MKGAF)

Merck's (MKGAF) CEO Stefan Oschmann on Q4 2017 Results - Earnings Call Transcript
Merck KGaA (MKGAF) Q4 2017 Results Earnings Conference Call March 8, 2018, 08:00 AM ET Executives Constantin Fest - Head of Investor Relations Stefan Oschmann - Chairman and Chief Executive Officer Marcus Kuhnert - Chief Financial Officer Analysts Peter Verdult - Citigroup ...
Source: SeekingAlpha
Date: March, 08 2018 22:19
Merck KGaA 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Merck KGaA in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: March, 08 2018 09:19
Merck KGaA's MS candidate evobrutinib successful in mid-stage study
A Phase 2b clinical trial evaluating Merck KGaA's ( OTCPK:MKGAF ) evobrutinib in patients with relapsing multiple sclerosis (MS) met the primary endpoint . Specifically, patients in the treatment group experienced statistically significant reductions in gadolinium-enhancing T1 lesions compa...
Source: SeekingAlpha
Date: March, 07 2018 10:53
Merck KGaA and Pfizer's Bavencio OK'd in Canada for rare type of skin cancer
Health Canada has approved Merck KGaA ( OTCPK:MKGAF ) unit EMD Serono and Pfizer's ( PFE +0.5% ) BAVENCIO (avelumab) for the treatment of Merkel cell carcinoma , a rare type of skin cancer. More news on: Merck KGaA, Pfizer Inc., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 22 2018 13:02
Merck KGaA to beef up manufacturing and distribution in Asia
Darmstadt, Germany-based Merck KGaA ( OTCPK:MKGAF ) will invest an additional €40M (US$47M) over the next two years to bolster its manufacturing and distribution presence in Asia. More news on: Merck KGaA, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 21 2018 10:23
Nestle backs away from Merck KGaA's consumer unit
Another potential suitor for Merck KGaA's ( OTCPK:MKGAF ) consumer health business has withdrawn from bidding . Food giant Nestle ( OTCPK:NSRGF )( OTCPK:NSRGY ) is the latest contender to back away after failing to arrive at mutually agreeable terms. Many observers believed it to be the fro...
Source: SeekingAlpha
Date: February, 02 2018 15:41
Nestle frontrunner for Merck KGaA's consumer health unit
Bloomberg reports that food behemoth Nestle ( OTCPK:NSRGF )( OTCPK:NSRGY ) has emerged as the lead bidder for Merck KGaA's ( OTCPK:MKGAF )( OTCPK:MKGAF ) consumer health business after other suitors, including Perrigo (NASDAQ: PRGO ) and PE firms Bain Capital and Cinven, withdrew. More n...
Source: SeekingAlpha
Date: January, 10 2018 16:25
Week In Review: 2017 Was Record Investment Year For China Life Science; Final Week Adds $669 Million
Deals and Financings Shanghai's SARI will pay $359 million to acquire a 90% interest in Group NMS, a Milan oncology biopharma. SARI is a biopharma investment firm affiliated with the Chinese Academy of Science research organization with the same name. SARI intends to bring NMS oncology dru...
Source: SeekingAlpha
Date: December, 31 2017 08:11
Merck KGaA's Bavencio + Pfizer's Inlyta a Breakthrough Therapy for first-line kidney cancer
The FDA designates the combination of Merck KGaA's ( OTCPK:MKGAF )( OTCPK:MKGAY ) BAVENCIO (avelumab) and Pfizer's ( PFE -0.3% ) INLYTA (axitinib) a Breakthrough Therapy for first-line treatment of advanced renal cell carcinoma, the most common form of kidney cancer. More news on: ...
Source: SeekingAlpha
Date: December, 21 2017 13:18
Britain's cost watchdog backs Novartis' MS med Extavia for use by NHS
Britain's service quality and cost advisor, the National Institute for Health and Care Excellence (NICE), approves National Health Service funding for Novartis' (NYSE: NVS ) Extavia (interferon beta-1b) for the treatment of relapsing-remitting multiple sclerosis or secondary progressive mu...
Source: SeekingAlpha
Date: December, 20 2017 07:31


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Merck KGaA (OTC: MKGAF)

Logo for Merck KGaA (OTC: MKGAF)

Merck KGaA is a global pharmaceutical, chemical and life science company with a history that began in and a future shaped by approximately , employees in countries. Merck KGaA s subsidiaries in North America operate using the umbrella brand EMD .


Contact Information



Current Management

  • KarlLudwig Kle Kley / CEO
  • Matthias Zachert / CFO
  • Constantin Fest / IR
  • IR Investor Relations / IR

Current Share Structure

  • Market Cap: $36,775,886,506 - 03/09/2018
  • Issue and Outstanding: 387,726,795 - 03/14/2016


Recent Filings from (OTC: MKGAF)

Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: July, 25 2017
Registration of depository shares evidenced by American Depository Receipts
Filing Type: F-6Filing Source: edgar
Filing Date: July, 18 2017


Daily Technical Chart for (OTC: MKGAF)

Daily Technical Chart for (OTC: MKGAF)

Stay tuned for daily updates and more on (OTC: MKGAF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MKGAF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MKGAF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of MKGAF and does not buy, sell, or trade any shares of MKGAF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer:



Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us